What are the guidelines for using Crestor (rosuvastatin) in patients with chronic kidney disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Rosuvastatin (Crestor) Use in Chronic Kidney Disease

For patients with chronic kidney disease, rosuvastatin is recommended with a maximum dose of 10 mg daily in severe renal impairment (CrCl <30 mL/min/1.73 m²), while no dosage adjustment is necessary for mild to moderate renal impairment. 1, 2

Dosing Recommendations Based on Renal Function

  • In patients with severe renal impairment (CrCl <30 mL/min/1.73 m²) not on hemodialysis, start with 5 mg once daily and do not exceed 10 mg once daily 1, 2
  • No dosage adjustment is necessary for patients with mild to moderate renal impairment, with standard dosing range of 5-40 mg daily 1, 2
  • Asian patients should initiate rosuvastatin at 5 mg once daily due to increased plasma concentrations, regardless of renal function 2

Indications for Statin Therapy in CKD

  • For adults ≥50 years with eGFR <60 mL/min/1.73 m² (CKD G3a-G5) not on dialysis or transplantation, statin or statin/ezetimibe combination is strongly recommended (1A) 3, 4
  • For adults ≥50 years with CKD and eGFR ≥60 mL/min/1.73 m² (CKD G1-G2), statin monotherapy is recommended (1B) 3, 4
  • For adults 18-49 years with CKD, statin therapy is suggested for those with at least one of: coronary disease, diabetes mellitus, prior ischemic stroke, or estimated 10-year cardiovascular risk >10% (2A) 3, 4

Benefits of Rosuvastatin in CKD

  • Rosuvastatin effectively reduces total cholesterol, LDL-C, triglycerides, and non-HDL-C levels in CKD patients 5
  • Studies suggest rosuvastatin may have renoprotective effects, including reduction in albuminuria and serum cystatin C levels 5, 6
  • In the JUPITER trial, rosuvastatin reduced first cardiovascular events by 45% and all-cause mortality by 44% in patients with moderate CKD 7
  • Some evidence suggests rosuvastatin may arrest the progression of renal disease in long-term treatment 8

Monitoring and Precautions

  • Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating rosuvastatin and adjust dosage if necessary 2
  • Risk factors for myopathy with rosuvastatin include age ≥65 years, uncontrolled hypothyroidism, renal impairment, and concomitant use with certain drugs 2
  • Monitor renal function periodically during treatment, as improvements in estimated GFR have been observed with rosuvastatin therapy 8, 6
  • Choose statin regimens that maximize absolute reduction in LDL cholesterol to achieve largest treatment benefits 3, 4

Drug Interactions in CKD Patients

  • Avoid concomitant use of rosuvastatin with cyclosporine or gemfibrozil 2
  • When rosuvastatin must be used with cyclosporine, do not exceed 5 mg once daily 2
  • When taking rosuvastatin with an aluminum and magnesium hydroxide combination antacid, administer rosuvastatin at least 2 hours before the antacid 2
  • Multiple other medications require rosuvastatin dose limitations (10-20 mg maximum) including certain antiviral medications 2

Common Pitfalls and Caveats

  • Failure to adjust rosuvastatin dosage in severe renal impairment can increase risk of myopathy and rhabdomyolysis 2
  • Asian patients are at higher risk for myopathy and require lower starting doses 2
  • Drug dosing errors are common in patients with renal impairment and can cause adverse effects 9
  • Consider complementing statin therapy with a plant-based "Mediterranean-style" diet to further reduce cardiovascular risk 3

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.